SCHEMBL3222610

SCHEMBL3222610

COc1ccc(NC(=O)c2cncc(-c3ccc(C)cc3)c2)cn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.62
KMT2A Q03164 6/20 0.62
KEAP1 Q14145 1/20 0.62
NFE2L2 Q16236 1/20 0.62
SCN10A Q9Y5Y9 4/20 0.59
SMN1; SMN2 Q16637 1/20 0.57
PABPC1 P11940 2/20 0.54
KCNH2 Q12809 1/20 0.53
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
CHRNA7 P36544 1/20 0.52
USP2 O75604 1/20 0.51
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
CLK2 P49760 1/20 0.50
CLK3 P49761 1/20 0.50
DYRK1A Q13627 1/20 0.50
ROCK2 O75116 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3211310 0.91 KMT2A (0.69) MEN1KMT2AKEAP1NFE2L2SCN10A
SCHEMBL3216340 0.89 KMT2A (0.67) MEN1KMT2AKEAP1NFE2L2SCN10A
SCHEMBL13947158 0.84 SMN1; SMN2 (0.65) MEN1KMT2AKEAP1NFE2L2SMN1; SMN2
SCHEMBL3203230 0.82 KMT2A (0.64) MEN1KMT2AKEAP1NFE2L2SCN10A
SCHEMBL3223614 0.81 SMN1; SMN2 (0.54) MEN1KMT2AKEAP1NFE2L2SMN1; SMN2
SCHEMBL1863548 0.81 SMN1; SMN2 (0.62) MEN1KMT2AKEAP1NFE2L2SMN1; SMN2
SCHEMBL3214121 0.81 MEN1 (0.61) MEN1KMT2AKEAP1NFE2L2SCN10A
SCHEMBL3208933 0.80 PTPN1 (0.56) MEN1KMT2AKEAP1NFE2L2SMN1; SMN2
SCHEMBL14082576 0.78 ROCK2 (0.70) MEN1KMT2AKEAP1NFE2L2SMN1; SMN2
SCHEMBL14082451 0.76 MEN1 (0.58) MEN1KMT2AKEAP1NFE2L2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
WO-2006022955-A2 TOPOISOMERASE INHIBITORS PROPHARMACON, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004701-A1 Topoisomerase inhibitors TOP1, TOP2A, TOP2B MEN1 2335/4885KMT2A 764/4885KEAP1 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.